Zealand Pharma A/S (OTCMKTS:ZLDPF) Upgraded at William Blair

William Blair upgraded shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) to a hold rating in a research note issued to investors on Thursday morning,Zacks.com reports.

A number of other analysts have also issued reports on the company. Cantor Fitzgerald upgraded Zealand Pharma A/S to a “strong-buy” rating in a report on Tuesday, January 21st. JPMorgan Chase & Co. started coverage on Zealand Pharma A/S in a report on Friday, November 8th. They issued an “overweight” rating for the company.

Zealand Pharma A/S Price Performance

Shares of OTCMKTS:ZLDPF opened at $97.78 on Thursday. The company has a debt-to-equity ratio of 0.03, a current ratio of 35.49 and a quick ratio of 35.49. The firm has a market capitalization of $6.94 billion, a PE ratio of -41.43 and a beta of 0.88. The business has a 50 day simple moving average of $101.00 and a two-hundred day simple moving average of $112.50. Zealand Pharma A/S has a 1 year low of $80.86 and a 1 year high of $141.74.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last announced its quarterly earnings results on Thursday, February 20th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.19. The firm had revenue of $1.30 million during the quarter, compared to analyst estimates of $28.11 million. Zealand Pharma A/S had a negative return on equity of 15.24% and a negative net margin of 1,725.03%. On average, equities analysts predict that Zealand Pharma A/S will post -2.19 EPS for the current year.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.